Clinical Trial of 6% Hydroxyethyl Starch (a New Plasma Expander)

Lack of nephrotoxicity by 6% hydroxyethyl starch 130/0.4 during hip arthroplasty: a randomized controlled trial.

BACKGROUND Hydroxyethyl starch (HES) is commonly used as plasma expander during surgery but may be nephrotoxic as seen in studies in patients with sepsis. The authors hypothesized that the possible nephrotoxicity of 6% HES 130/0.4 could be revealed by measurements of urinary excretion of neutrophil gelatinase-associated lipocalin (u-NGAL) in patients with normal renal function during hip arthro...

Early fluid resuscitation with hydroxyethyl starch 130/0.4 (6%) in severe burn injury: a randomized, controlled, double-blind clinical trial

INTRODUCTION There are limited data on the efficacy of early fluid resuscitation with third-generation hydroxyethyl starch (HES 130) in burn injury. Adverse effects of HES on survival and organ function have been reported. METHODS In this randomized, controlled, double-blind trial, 48 patients with severe burn injury were assigned to receive either lactated Ringer's solution plus 6% HES 130/0...

Plasma expansion during granulocyte procurement: cumulative effects of hydroxyethyl starch.

Hydroxyethyl starch (HES) has found widespread use to increase the efficiency of granulocyte collection. Although there is some concern about the possible harmful side effects on the donor. such as plasma expansion. these are believed to be shortlived. since the hematocrit returns to baseline by 24 hr. We have used ‘31l-albumin to measure the actual changes in plasma volume in donors who receiv...

Early clinical experience with a newly formulated hydroxyethyl starch--Hextend.

Influence of hydroxyethyl starch (6% HES 130/0.4) administration on hematology and clinical chemistry parameters.

BACKGROUND The chemical inertness of hydroxyethyl starch (HES) might cause interferences of the colloid with a variety of laboratory tests. We aimed to evaluate potential influences of HES 130/0.4, the newest HES type, on several common hematology and clinical chemistry parameters. METHODS AND RESULTS A convenient sample of 25 patients scheduled for rheological therapy with 500 mL 6% HES 130/...